---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026119"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:38:53.572133+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# uniQure reports FY2022 net loss of $126.8M; revenue drops to $106.5M from $524M

## Summary
- Net loss of $126.8M ($2.71 loss per share) vs net income of $329.6M in 2021.
- Revenue of $106.5M, down 80% YoY, primarily due to absence of large license revenue from CSL Behring transaction.
- Cash and investments $392.8M as of Dec 31, 2022; expects funding into 2025 assuming $100M milestone from HEMGENIX first U.S. sale.
- HEMGENIX received U.S. and EU marketing approvals for hemophilia B; eligible for $100M and $75M milestone payments from CSL Behring.
- Pipeline: AMT-130 Huntington's update expected Q2 2023; AMT-162 (SOD1 ALS) and AMT-260 (epilepsy) Phase I/II trials expected H2 2023.

## SEC filing metadata
- accession: 0001104659-23-026119
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465923026119/0001104659-23-026119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465923026119/tm237999d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026119
- JSON: https://secwatch.observer/filing/0001104659-23-026119.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026119.txt

## Key facts
- Earnings Releases
  uniQure N.V. reported financial results for the full year ended December 31, 2022.
  - Period: the full year ended December 31, 2022
  - Result: reported results
  source text: On February 27, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the full year ended December 31, 2022 and highlighting company progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923026119/0001104659-23-026119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.